Evidence map›Paper›PMID 42756586›Full record

ArticleUrology case reports2026

A case report of a rare retroperitoneal sarcoma in an adolescent.

Xusong Pang, Feiyu Yin, Sinan Yang, Zhaojie Kang, Mei Wu, Junpeng Sun, Kun Zhang, Longguo Dai, Haiyang Jiang, Chongjian Zhang and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xusong PangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Feiyu YinThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Sinan YangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Zhaojie KangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Mei WuThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Junpeng SunThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Kun ZhangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Longguo DaiThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Haiyang JiangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Chongjian ZhangThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Ying BiThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.
Yu BaiThe Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Department of Urology I, Kunming, 650118, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adolescent retroperitoneal sarcoma (RPS) poses significant decision-making challenges due to complex subtypes and limited molecular diagnosis. A 16-year-old male with a 13.8 cm retroperitoneal mass underwent R0 en bloc resection (with left adrenal gland). Pathology favored high-grade fibrosarcoma. He completed 5 cycles of adjuvant Ifosfamide and Doxorubicin. At 17 months post-surgery, surveillance shows no disease recurrence. When molecular testing is unavailable for large, high-grade adolescent RPS, combining R0 en bloc resection with intensive adjuvant chemotherapy remains an effective strategy for favorable outcomes.

Indexed as

Adjuvant chemotherapyAdolescentFibrosarcomaRetroperitoneal sarcoma

Identifiers

PMID42756586
PMCPMC13583953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.